The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. - Ruan DY; Wu HX; Luo SX; Huang WW; Liang XJ; Niu ZX; Dang Q; Li HL; Pan ZY; Lu HX; Zhang YQ; Li XY; et al. (Nature medicine, 2025)